Protagenic Total Assets from 2010 to 2024

PTIXW Stock

USD 0.01 0.01 80.00%

Protagenic Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 4.1 M in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1996-06-30

Previous Quarter

1.5 M

Current Value

1.5 M

Quarterly Volatility

38.1 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Protagenic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protagenic Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.8 K, Interest Expense of 137.6 K or Selling General Administrative of 1.1 M, as well as many indicators such as Price To Sales Ratio of 0.28, Dividend Yield of 0.0 or PTB Ratio of 1.11. Protagenic financial statements analysis is a perfect complement when working with Protagenic Therapeutics Valuation or Volatility modules.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Protagenic Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Protagenic Therapeutics over the last few years. Total assets refers to the total amount of Protagenic Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Protagenic Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Protagenic Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protagenic Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 4.32 M

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Total Assets

Timeline

Protagenic Total Assets Regression Statistics

	Arithmetic Mean	3,233,482
	Geometric Mean	1,483,869
	Coefficient Of Variation	118.49
	Mean Deviation	2,992,067
	Median	954,000
	Standard Deviation	3,831,399
	Sample Variance	14.7T
	Range	10.9M
	R-Value	0.21
	Mean Square Error	15.1T
	R-Squared	0.05
	Significance	0.45
	Slope	181,902
	Total Sum of Squares	205.5T

Protagenic Total Assets History

	2024	4.1 M
	2023	4.3 M
	2022	8 M
	2021	11.1 M
	2020	879.2 K
	2019	842.3 K
	2018	696.9 K

Other Fundumenentals of Protagenic Therapeutics

Intangibles To Total Assets

Protagenic Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Accounts Payable	Short Term Investments	Intangible Assets	Current Deferred Revenue	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt	Capital Surpluse	Short Long Term Debt
Total Assets		0.63	-0.02	0.19	-0.48	-0.48	-0.17	0.88	0.12	-0.24	-0.24	0.81	-0.27	0.57	0.73	0.73	0.11	-0.1	-0.09	-0.09
Total Stockholder Equity	0.63		-0.54	0.85	-0.16	-0.16	-0.87	0.64	-0.66	-0.9	-0.89	0.53	0.03	0.26	0.49	0.49	-0.03	0.07	-0.26	-0.26
Net Debt	-0.02	-0.54		-0.55	-0.42	-0.42	0.66	-0.23	0.68	0.61	0.61	-0.06	-0.43	0.32	-0.12	-0.12	0.16	0.02	0.38	0.38
Retained Earnings	0.19	0.85	-0.55		-0.13	-0.13	-0.98	0.15	-0.84	-0.99	-0.99	0.09	-0.07	0.15	0.06	0.06	-0.01	0.1	-0.04	-0.04
Net Receivables	-0.48	-0.16	-0.42	-0.13		1.0	-0.07	-0.04	-0.41	0.04	0.05	0.0	0.82	-0.95	0.15	0.15	-0.2	0.18	-0.41	-0.41
Good Will	-0.48	-0.16	-0.42	-0.13	1.0		-0.07	-0.04	-0.41	0.04	0.05	0.0	0.82	-0.95	0.15	0.15	-0.2	0.18	-0.41	-0.41
Total Liab	-0.17	-0.87	0.66	-0.98	-0.07	-0.07		-0.22	0.91	0.99	0.99	-0.15	-0.12	0.01	-0.16	-0.15	0.08	-0.12	0.17	0.17
Total Current Assets	0.88	0.64	-0.23	0.15	-0.04	-0.04	-0.22		-0.07	-0.25	-0.24	0.92	0.19	0.17	0.89	0.89	0.05	0.01	-0.37	-0.37
Short Term Debt	0.12	-0.66	0.68	-0.84	-0.41	-0.41	0.91	-0.07		0.86	0.86	-0.08	-0.32	0.41	-0.14	-0.14	0.03	-0.17	0.13	0.13
Common Stock	-0.24	-0.9	0.61	-0.99	0.04	0.04	0.99	-0.25	0.86		1.0	-0.16	-0.04	-0.1	-0.15	-0.14	0.07	-0.16	0.15	0.15
Accounts Payable	-0.24	-0.89	0.61	-0.99	0.05	0.05	0.99	-0.24	0.86	1.0		-0.15	-0.03	-0.11	-0.14	-0.14	0.07	-0.15	0.14	0.14
Short Term Investments	0.81	0.53	-0.06	0.09	0.0	0.0	-0.15	0.92	-0.08	-0.16	-0.15		0.07	0.04	0.98	0.98	0.12	-0.14	-0.12	-0.12
Intangible Assets	-0.27	0.03	-0.43	-0.07	0.82	0.82	-0.12	0.19	-0.32	-0.04	-0.03	0.07		-0.64	0.16	0.16	-0.24	0.3	-0.79	-0.79
Current Deferred Revenue	0.57	0.26	0.32	0.15	-0.95	-0.95	0.01	0.17	0.41	-0.1	-0.11	0.04	-0.64		-0.1	-0.1	0.05	-0.11	0.1	0.1
Net Invested Capital	0.73	0.49	-0.12	0.06	0.15	0.15	-0.16	0.89	-0.14	-0.15	-0.14	0.98	0.16	-0.1		1.0	0.12	-0.09	-0.17	-0.17
Net Working Capital	0.73	0.49	-0.12	0.06	0.15	0.15	-0.15	0.89	-0.14	-0.14	-0.14	0.98	0.16	-0.1	1.0		0.15	-0.09	-0.16	-0.16
Capital Stock	0.11	-0.03	0.16	-0.01	-0.2	-0.2	0.08	0.05	0.03	0.07	0.07	0.12	-0.24	0.05	0.12	0.15		-0.06	0.42	0.42
Long Term Debt	-0.1	0.07	0.02	0.1	0.18	0.18	-0.12	0.01	-0.17	-0.16	-0.15	-0.14	0.3	-0.11	-0.09	-0.09	-0.06		-0.27	-0.27
Capital Surpluse	-0.09	-0.26	0.38	-0.04	-0.41	-0.41	0.17	-0.37	0.13	0.15	0.14	-0.12	-0.79	0.1	-0.17	-0.16	0.42	-0.27		1.0
Short Long Term Debt	-0.09	-0.26	0.38	-0.04	-0.41	-0.41	0.17	-0.37	0.13	0.15	0.14	-0.12	-0.79	0.1	-0.17	-0.16	0.42	-0.27	1.0

Click cells to compare fundamentals

About Protagenic Therapeutics Financial Statements

Protagenic Therapeutics investors use historical fundamental indicators, such as Protagenic Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Protagenic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	4.3 M	4.1 M
Intangibles To Total Assets	0.18	0.19

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Protagenic Stock Analysis

When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC